Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long‐wavelength ultraviolet light

Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and... BACKGROUND: Viral contamination of platelet (PLT) concentrates can result in transfusion‐transmitted diseases. A photochemical treatment (PCT) process with amotosalen‐HCl and long‐wavelength ultraviolet light (UVA), which cross‐links nucleic acids, was developed to inactivate viruses and other pathogens in PLT concentrates. STUDY DESIGN AND METHODS: High titers of pathogenic or blood‐borne viruses, representing 10 different families, were added to single‐donor PLT concentrates containing 3.0 × 1011 to 6.0 × 1011 PLTs in approximately 300 mL of 35 percent plasma and 65 percent PLT additive solution (InterSol). After PCT with 150 µmol per L amotosalen and 3 J per cm2 UVA, residual viral infectivity was assayed by sensitive cell culture or animal systems. RESULTS: Enveloped viruses were uniformly sensitive to inactivation by PCT whereas nonenveloped viruses demonstrated variable inactivation. Log reduction of enveloped viruses for cell‐free HIV‐1 was >6.2; for cell‐associated HIV‐1, >6.1; for clinical isolate HIV‐1, >3.4; for clinical isolate HIV‐2, >2.5; for HBV, >5.5; for HCV, >4.5; for DHBV, >6.2; for BVDV, >6.0; for HTLV‐I, 4.2; for HTLV‐II, 4.6; for CMV, >5.9; for WNV, >5.5; for SARS‐HCoV, >5.8; and for vaccinia virus, >4.7. Log reduction of nonenveloped viruses for human adenovirus 5 was >5.2; for parvovirus B19, 3.5‐>5.0; for bluetongue virus, 5.6‐5.9; for feline conjunctivitis virus, 1.7‐2.4; and for simian adenovirus 15, 0.7‐2.3. CONCLUSION: PCT inactivates a broad spectrum of pathogenic, blood‐borne viruses. Inactivation of viruses in PLT concentrates with amotosalen and UVA offers the potential to prospectively prevent the majority of PLT transfusion‐associated viral diseases. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Transfusion Wiley

Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long‐wavelength ultraviolet light

Download PDF
11 pages

Loading next page...
 
/lp/wiley/inactivation-of-viruses-in-platelet-concentrates-by-photochemical-QT69jlV0JD

References (113)

Publisher
Wiley
Copyright
Copyright © 2005 Wiley Subscription Services, Inc., A Wiley Company
ISSN
0041-1132
eISSN
1537-2995
DOI
10.1111/j.0041-1132.2005.04316.x
pmid
15819680
Publisher site
See Article on Publisher Site

Abstract

BACKGROUND: Viral contamination of platelet (PLT) concentrates can result in transfusion‐transmitted diseases. A photochemical treatment (PCT) process with amotosalen‐HCl and long‐wavelength ultraviolet light (UVA), which cross‐links nucleic acids, was developed to inactivate viruses and other pathogens in PLT concentrates. STUDY DESIGN AND METHODS: High titers of pathogenic or blood‐borne viruses, representing 10 different families, were added to single‐donor PLT concentrates containing 3.0 × 1011 to 6.0 × 1011 PLTs in approximately 300 mL of 35 percent plasma and 65 percent PLT additive solution (InterSol). After PCT with 150 µmol per L amotosalen and 3 J per cm2 UVA, residual viral infectivity was assayed by sensitive cell culture or animal systems. RESULTS: Enveloped viruses were uniformly sensitive to inactivation by PCT whereas nonenveloped viruses demonstrated variable inactivation. Log reduction of enveloped viruses for cell‐free HIV‐1 was >6.2; for cell‐associated HIV‐1, >6.1; for clinical isolate HIV‐1, >3.4; for clinical isolate HIV‐2, >2.5; for HBV, >5.5; for HCV, >4.5; for DHBV, >6.2; for BVDV, >6.0; for HTLV‐I, 4.2; for HTLV‐II, 4.6; for CMV, >5.9; for WNV, >5.5; for SARS‐HCoV, >5.8; and for vaccinia virus, >4.7. Log reduction of nonenveloped viruses for human adenovirus 5 was >5.2; for parvovirus B19, 3.5‐>5.0; for bluetongue virus, 5.6‐5.9; for feline conjunctivitis virus, 1.7‐2.4; and for simian adenovirus 15, 0.7‐2.3. CONCLUSION: PCT inactivates a broad spectrum of pathogenic, blood‐borne viruses. Inactivation of viruses in PLT concentrates with amotosalen and UVA offers the potential to prospectively prevent the majority of PLT transfusion‐associated viral diseases.

Journal

Transfusion – Wiley

Published: Apr 1, 2005

There are no references for this article.